Noxopharm Limited (ASX: NOX) - Share Price

Current share price for NOX : $0.091 0.002 (2.15%)⁺

Noxopharm Limited (NOX), an ASX-listed company, is a clinical-stage Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a range of mRNA medicines. The company utilises in house capabilities and strategic partnerships with researchers to build a growing pipeline of new proprietary drugs based on two technology platforms - Sofra (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma (oncology).

NOX General Information ⁺

ASX Code	NOX
Website	N/A
Industry/Sector	Biotechnology
Market Cap ($M)	27
NOX Share Price	$0.091
Day High	$0.094
Day Low	$0.091
Last Close	$0.093
NOX Share Price Movement	$0.00 ( 2.15% )

Prices as at 16:40, 10 Jul 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Noxopharm Limited (NOX) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Noxopharm Limited (NOX) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Noxopharm Limited (NOX) price-sensitive announcements

NOX - SOF-SKN manufacturing begins to ensure clinical trial readi

Noxopharm Limited, an Australian clinical-stage biotech company, has started the manufactu

Noxopharm Limited (NOX)
9 Jun 2026 | 8:29 AM

NOX - New data confirms cancer-fighting potential

Noxopharm Limited, an Australian clinical-stage biotech company, has released promising ne

Noxopharm Limited (NOX)
26 May 2026 | 8:21 AM

NOX - Noxopharms Sofra assets to be presented at global conference

Noxopharm Limited announced that their Sofra™ technology platform will be featured at the

Noxopharm Limited (NOX)
20 May 2026 | 9:21 AM

NOX - Noxopharm progresses US regulatory strategy

Noxopharm Limited is taking strategic steps to progress its US regulatory strategy by prep

Noxopharm Limited (NOX)
6 May 2026 | 8:13 AM

Noxopharm Limited (NOX) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Noxopharm Limited (NOX) ORDINARY FULLY PAID	Health Care	$28	Pre-IND meeting request with US FDA	7 Jul 2026 9:34AM	$0.094	$0.091	fallen by 3.19%
Noxopharm Limited (NOX) ORDINARY FULLY PAID	Health Care	$28	Sofr platform versatility shown via childbirth MRFF grant	2 Jul 2026 8:15AM	$0.085	$0.091	risen by 7.06%
Noxopharm Limited (NOX) ORDINARY FULLY PAID	Health Care	$28	Fast-tracking of cancer program via novel animal model	1 Jul 2026 9:50AM	$0.087	$0.091	risen by 4.60%
Noxopharm Limited (NOX) ORDINARY FULLY PAID	Health Care	$28	SOF-SKN manufacturing begins to ensure clinical trial readi	9 Jun 2026 8:29AM	$0.081	$0.091	risen by 12.35%
Noxopharm Limited (NOX) ORDINARY FULLY PAID	Health Care	$28	Change of Director's Interest Notice	1 Jun 2026 4:23PM	$0.085	$0.091	risen by 7.06%
Noxopharm Limited (NOX) ORDINARY FULLY PAID	Health Care	$28	New data confirms cancer-fighting potential	26 May 2026 8:21AM	$0.060	$0.091	risen by 51.67%

NOX Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2025A	-$4.88	-$1.70	36.90%	0.00%	0.0%
2024A	-$3.58	-$1.20	-76.30%	0.00%	0.0%
2023A	-$15.06	-$5.20	-19.70%	0.00%	0.0%

NOX Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A
CSL Limited (CSL)	$60,118M	0.1108	-0.1205	0.0167	13.4607	15.3041	15.0521	3.55%	2.90%	3.02%
Clinuvel Pharmaceuticals Limited (CUV)	$527M	0.0287	0.0000	0.0000	14.5543	0.0000	0.0000	0.48%	0.00%	0.00%
Mesoblast Limited (MSB)	$2,719M	0.0301	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Noxopharm Limited (NOX)	$29M	0.3689	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Telix Pharmaceuticals Limited (TLX)	$5,749M	-1.3893	0.0000	-0.1303	0.0000	310.8257	357.3840	0.00%	0.00%	0.00%

NOX Directors

Name	Position	Start Date
Dr Gisela Mautner	Chief Executive Officer, Managing Director	1 Feb 2022
Mr Boris Patkin	Non-Executive Director	25 Mar 2020
Mr Frederick (Fred) Bart	Non-Executive Director, Non-Executive Chairman	8 May 2020
Mr Peter Ashley Marks	Non-Executive Director, Non-Executive Deputy Chairman	15 Mar 2016

Noxopharm Limited (NOX) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
25 May 2026	PATKIN, Boris	Transfer	Direct Shares	630,000	$0.060	$37,800.000
25 May 2026	PATKIN, Boris	Transfer	Indirect Shares	630,000	$0.060	$37,800.000
12 Dec 2025	BART, Frederick (Fred)	Issued	Convertibles	1,250,000	$1.000	$1,250,000.000

See all changes in directors' interest & trades for Noxopharm Limited (NOX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

NOX Management

Name	Position
Shawn Pieter Van Boheemen	Company Secretary

NOX Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Noxopharm Limited (NOX). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
34,249,106 (11.72%)	Milligene Pty Ltd

NOX Calendar of Events

Date	Event
26 February 2027	Report (Interim)
12 October 2026	Report (Annual)
28 September 2026	Report (Annual)
28 August 2026	Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us